The validity of cost-effectiveness analyses of tight glycemic control. A systematic survey of economic evaluations of pharmacological interventions in patients with type 2 diabetes

[1]  B. Zinman,et al.  Effect of Linagliptin vs Glimepiride on Major Adverse Cardiovascular Outcomes in Patients With Type 2 Diabetes: The CAROLINA Randomized Clinical Trial. , 2019, JAMA.

[2]  W. Aronow.  Faculty Opinions recommendation of SGLT2 inhibitors for primary and secondary prevention of cardiovascular and renal outcomes in type 2 diabetes: a systematic review and meta-analysis of cardiovascular outcome trials. , 2019, Faculty Opinions – Post-Publication Peer Review of the Biomedical Literature.

[3]  Marc P. Bonaca,et al.  SGLT2 inhibitors for primary and secondary prevention of cardiovascular and renal outcomes in type 2 diabetes: a systematic review and meta-analysis of cardiovascular outcome trials , 2019, The Lancet.

[4]  Ping Zhang,et al.  Economic Costs of Diabetes in the U.S. in 2017 , 2018, Diabetes Care.

[5]  Adrian F Hernandez,et al.  Cardiovascular outcomes with glucagon-like peptide-1 receptor agonists in patients with type 2 diabetes: a meta-analysis. , 2017, The lancet. Diabetes & endocrinology.

[6]  Hengjin Dong,et al.  Cost‐effectiveness of exenatide twice daily vs insulin glargine as add‐on therapy to oral antidiabetic agents in patients with type 2 diabetes in China , 2017, Diabetes, obesity & metabolism.

[7]  B. Hunt,et al.  Cost-Effectiveness of IDegLira Versus Insulin Intensification Regimens for the Treatment of Adults with Type 2 Diabetes in the Czech Republic , 2017, Diabetes Therapy.

[8]  W. Miller,et al.  Hidden costs: The ethics of cost-effectiveness analyses for health interventions in resource-limited settings , 2017, Global public health.

[9]  J. Yfantopoulos,et al.  Cost effectiveness of vildagliptin versus glimepiride as add-on treatment to metformin for the treatment of diabetes mellitus type 2 patients in Greece , 2017, Cost Effectiveness and Resource Allocation.

[10]  K. Thavorn,et al.  Cost-effectiveness of insulin detemir versus insulin glargine for Thai type 2 diabetes from a payer’s perspective , 2017, Journal of medical economics.

[11]  H. Krumholz,et al.  Hospital Readmissions among Commercially Insured and Medicare Advantage Beneficiaries with Diabetes and the Impact of Severe Hypoglycemic and Hyperglycemic Events , 2017, Journal of General Internal Medicine.

[12]  W. Valentine,et al.  Long-term Cost-effectiveness of Two GLP-1 Receptor Agonists for the Treatment of Type 2 Diabetes Mellitus in the Italian Setting: Liraglutide Versus Lixisenatide. , 2017, Clinical therapeutics.

[13]  W. Valentine,et al.  Evaluation of the long‐term cost‐effectiveness of liraglutide vs lixisenatide for treatment of type 2 diabetes mellitus in the UK setting , 2017, Diabetes, obesity & metabolism.

[14]  B. Hunt,et al.  Modeling the Long-Term Cost-Effectiveness of IDegLira in Patients with Type 2 Diabetes Who are Failing To Meet Glycemic Targets on Basal Insulin Alone in The Netherlands , 2017, Diabetes Therapy.

[15]  W. Valentine,et al.  IDegLira Versus Insulin Glargine U100: A Long-term Cost-effectiveness Analysis in the US Setting , 2017, Diabetes Therapy.

[16]  R. Wojcik,et al.  Cost-Effectiveness of Liraglutide Versus Dapagliflozin for the Treatment of Patients with Type 2 Diabetes Mellitus in the UK , 2017, Diabetes Therapy.

[17]  W. Valentine,et al.  Evaluation of the long-term cost-effectiveness of IDegLira versus liraglutide added to basal insulin for patients with type 2 diabetes failing to achieve glycemic control on basal insulin in the USA , 2017, Journal of medical economics.

[18]  W. Valentine,et al.  Liraglutide Versus Lixisenatide: Long-Term Cost-Effectiveness of GLP-1 Receptor Agonist Therapy for the Treatment of Type 2 Diabetes in Spain , 2017, Diabetes Therapy.

[19]  S. Zhai,et al.  Cost-effectiveness analysis of dapagliflozin versus glimepiride as monotherapy in a Chinese population with type 2 diabetes mellitus , 2017, Current medical research and opinion.

[20]  D. Alexiou,et al.  The cost-effectiveness of dulaglutide versus liraglutide for the treatment of type 2 diabetes mellitus in Spain in patients with BMI ≥30 kg/m2 , 2017, Journal of medical economics.

[21]  Å. Ericsson,et al.  Cost Effectiveness of Insulin Degludec Plus Liraglutide (IDegLira) in a Fixed Combination for Uncontrolled Type 2 Diabetes Mellitus in Sweden , 2017, Applied Health Economics and Health Policy.

[22]  Hengjin Dong,et al.  Cost-Effectiveness of Saxagliptin versus Acarbose as Second-Line Therapy in Type 2 Diabetes in China , 2016, PloS one.

[23]  S. Zhai,et al.  Cost-Effectiveness of Dapagliflozin versus Acarbose as a Monotherapy in Type 2 Diabetes in China , 2016, PloS one.

[24]  J. Gordon,et al.  The Cost-Effectiveness of Alogliptin Versus Sulfonylurea as Add-on Therapy to Metformin in Patients with Uncontrolled Type 2 Diabetes Mellitus , 2016, Diabetes Therapy.

[25]  K. Thavorn,et al.  Cost-effectiveness of dipeptidyl peptidase-4 inhibitor monotherapy in elderly type 2 diabetes patients in Thailand , 2016, ClinicoEconomics and outcomes research : CEOR.

[26]  Lawrence A Leiter,et al.  Semaglutide and Cardiovascular Outcomes in Patients with Type 2 Diabetes. , 2016, The New England journal of medicine.

[27]  V. Montori,et al.  Glycemic Control for Patients With Type 2 Diabetes Mellitus: Our Evolving Faith in the Face of Evidence , 2016, Circulation. Cardiovascular quality and outcomes.

[28]  B. Wolffenbuttel,et al.  The cost-effectiveness of exenatide twice daily (BID) vs insulin lispro three times daily (TID) as add-on therapy to titrated insulin glargine in patients with type 2 diabetes , 2016, Journal of medical economics.

[29]  M. Davies,et al.  Cost Effectiveness of IDegLira vs. Alternative Basal Insulin Intensification Therapies in Patients with Type 2 Diabetes Mellitus Uncontrolled on Basal Insulin in a UK Setting , 2016, PharmacoEconomics.

[30]  S. Grandy,et al.  Cost-effectiveness analysis of exenatide once-weekly versus dulaglutide, liraglutide, and lixisenatide for the treatment of type 2 diabetes mellitus: an analysis from the UK NHS perspective , 2016, Journal of medical economics.

[31]  Yan Wang,et al.  Long-Term Effectiveness and Cost-Effectiveness of Metformin Combined with Liraglutide or Exenatide for Type 2 Diabetes Mellitus Based on the CORE Diabetes Model Study , 2016, PloS one.

[32]  John B Buse,et al.  Liraglutide and Cardiovascular Outcomes in Type 2 Diabetes. , 2016, The New England journal of medicine.

[33]  N. Maniadakis,et al.  Cost-Effectiveness of Dapagliflozin as Add-On to Metformin for the Treatment of Type 2 Diabetes Mellitus in Greece , 2016, Clinical Drug Investigation.

[34]  Y. Reznik,et al.  Cost-effectiveness of continuous subcutaneous insulin infusion in people with type 2 diabetes in the Netherlands , 2016, Journal of medical economics.

[35]  K. Thavorn,et al.  Long-Term Cost-Effectiveness of Insulin Glargine Versus Neutral Protamine Hagedorn Insulin for Type 2 Diabetes in Thailand , 2016, Applied Health Economics and Health Policy.

[36]  B. Hunt,et al.  Cost-utility of albiglutide versus insulin lispro, insulin glargine, and sitagliptin for the treatment of type 2 diabetes in the US , 2016, Journal of Medical Economics.

[37]  R. Roussel,et al.  Evaluation of the long-term cost-effectiveness of liraglutide therapy for patients with type 2 diabetes in France , 2016, Journal of medical economics.

[38]  D. Mauricio,et al.  Análisis de coste-efectividad de saxagliptina como tratamiento triple oral (con metformina y una sulfonilurea) en el manejo de la diabetes tipo 2 en España , 2016 .

[39]  B. Zinman,et al.  Empagliflozin, Cardiovascular Outcomes, and Mortality in Type 2 Diabetes. , 2015, The New England journal of medicine.

[40]  S. Grandy,et al.  Cost-Effectiveness Analysis of Exenatide Once-Weekly Versus Dulaglutide, Liraglutide and Lixisenatide for the Treatment of Type 2 Diabetes Mellitus: An Analysis from the UK NHS Perspective. , 2015, Value in health : the journal of the International Society for Pharmacoeconomics and Outcomes Research.

[41]  M. Pencina,et al.  Effect of Sitagliptin on Cardiovascular Outcomes in Type 2 Diabetes. , 2015, The New England journal of medicine.

[42]  Deepak L. Bhatt,et al.  Saxagliptin and cardiovascular outcomes in patients with type 2 diabetes mellitus. , 2013, The New England journal of medicine.

[43]  John Hornberger,et al.  Computer Modeling of Diabetes and Its Complications , 2007, Diabetes Care.

[44]  M C Ashe,et al.  Does a home-based strength and balance programme in people aged ≥80 years provide the best value for money to prevent falls? A systematic review of economic evaluations of falls prevention interventions , 2009, British Journal of Sports Medicine.

[45]  D. Moher,et al.  Preferred reporting items for systematic reviews and meta-analyses: the PRISMA Statement , 2009, BMJ : British Medical Journal.

[46]  S Bryan,et al.  The use of economic evaluations in NHS decision-making: a review and empirical investigation. , 2008, Health technology assessment.

[47]  F. Schmidt.  Meta-Analysis , 2008 .

[48]  S. Nissen,et al.  Effect of rosiglitazone on the risk of myocardial infarction and death from cardiovascular causes. , 2007, The New England journal of medicine.

[49]  Alan Brennan,et al.  Computer Modeling of Diabetes and Its Complications , 2007, Diabetes Care.

[50]  Ping Zhang,et al.  Computer modeling of diabetes and its complications: a report on the Fifth Mount Hood challenge meeting. , 2007, Value in health : the journal of the International Society for Pharmacoeconomics and Outcomes Research.

[51]  W. Gerth,et al.  Use of cost-effectiveness analysis in health-care resource allocation decision-making: how are cost-effectiveness thresholds expected to emerge? , 2004, Value in health : the journal of the International Society for Pharmacoeconomics and Outcomes Research.

[52]  Plamen Nikolov,et al.  Economic Costs of Diabetes in the U.S. in 2002 , 2003, Diabetes care.

[53]  Sean D Sullivan,et al.  Development and Validation of a Grading System for the Quality of Cost-Effectiveness Studies , 2003, Medical care.

[54]  M. Drummond,et al.  Health Care Technology: Effectiveness, Efficiency and Public Policy@@@Methods for the Economic Evaluation of Health Care Programmes , 1988 .

[55]  N. Maniadakis,et al.  Cost Effectiveness of Exenatide Once Weekly Versus Insulin Glargine and Liraglutide for the Treatment of Type 2 Diabetes Mellitus in Greece , 2017, Clinical Drug Investigation.

[56]  M. Willis,et al.  Cost-effectiveness of Canagliflozin versus Sitagliptin When Added to Metformin and Sulfonylurea in Type 2 Diabetes in Canada. , 2016, Journal of population therapeutics and clinical pharmacology = Journal de la therapeutique des populations et de la pharamcologie clinique.

[57]  Franziska Wulf,et al.  Methods For The Economic Evaluation Of Health Care Programmes , 2016 .

[58]  Esther Duflo,et al.  Comparative Cost-Effectiveness Analysis to Inform Policy in Developing Countries: A General Framework with Applications for Education , 2013 .

[59]  D. Moher,et al.  Nonalcoholic Fatty Liver Disease and Acute Ischemic Stroke , 2010 .

[60]  D. Moher,et al.  Preferred reporting items for systematic reviews and meta-analyses: the PRISMA statement. , 2010, International journal of surgery.

[61]  D. Moher,et al.  Preferred reporting items for systematic reviews and meta-analyses: the PRISMA statement. , 2009, Journal of clinical epidemiology.

[62]  J. Hay,et al.  Examining the Value and Quality of Health Economic Analyses: Implications of Utilizing the QHES , 2003, Journal of managed care pharmacy : JMCP.